Loading…

Plasma proteomic signature of human longevity

The identification of protein targets that exhibit anti‐aging clinical potential could inform interventions to lengthen the human health span. Most previous proteomics research has been focused on chronological age instead of longevity. We leveraged two large population‐based prospective cohorts wit...

Full description

Saved in:
Bibliographic Details
Published in:Aging cell 2024-06, Vol.23 (6), p.e14136-n/a
Main Authors: Liu, Xiaojuan, Axelsson, Gisli Thor, Newman, Anne B., Psaty, Bruce M., Boudreau, Robert M., Wu, Chenkai, Arnold, Alice M., Aspelund, Thor, Austin, Thomas R., Gardin, Julius M., Siggeirsdottir, Kristin, Tracy, Russell P., Gerszten, Robert E., Launer, Lenore J., Jennings, Lori L., Gudnason, Vilmundur, Sanders, Jason L., Odden, Michelle C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The identification of protein targets that exhibit anti‐aging clinical potential could inform interventions to lengthen the human health span. Most previous proteomics research has been focused on chronological age instead of longevity. We leveraged two large population‐based prospective cohorts with long follow‐ups to evaluate the proteomic signature of longevity defined by survival to 90 years of age. Plasma proteomics was measured using a SOMAscan assay in 3067 participants from the Cardiovascular Health Study (discovery cohort) and 4690 participants from the Age Gene/Environment Susceptibility‐Reykjavik Study (replication cohort). Logistic regression identified 211 significant proteins in the CHS cohort using a Bonferroni‐adjusted threshold, of which 168 were available in the replication cohort and 105 were replicated (corrected p value
ISSN:1474-9718
1474-9726
1474-9726
DOI:10.1111/acel.14136